In addition to our own research and development activities, Crucell has formed strategic agreements with several leading companies. Through these agreements, our technologies are playing a vital role in the development of a number of vaccine and antibody products.

DSM Biologics

In December 2002, Crucell formed an alliance with DSM Biologics to license Crucell’s PER.C6^® human cell line as a production platform for monoclonal antibodies and recombinant proteins. The combination of the PER.C6^® human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. Furthering this commitment to the PER.C6^® cell line, Crucell and DSM have established a joint PER.C6^® R&D Center in Cambridge, Massachusetts, named PERCIVIA. The innovations resulting from this partnership will be available to licensees to further enhance their development capabilities.

 

• www.dsmbiologics.com
• www.percivia.com

Johnson & Johnson

An exciting strategic collaboration between Crucell and Johnson & Johnson (JNJ) was announced in September 2009.

 

The focus of the strategic partnership will be the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza, as well as other diseases.

 

Johnson & Johnson, through its affiliate JHC Nederland B.V., has also purchased 14.6 million newly issued ordinary shares of Crucell, representing approximately 18% of Crucell's outstanding ordinary shares, for an aggregate purchase price of € 301.8 million. In addition, the companies have agreed to development milestones and royalty payments based on the successful development and commercialization of products in connection with the collaboration.

 

• www.jnj.com

 

MedImmune

In October 2007, MedImmune and Crucell entered into an exclusive license and research collaboration to further develop and commercialize one of Crucell’s panels of bacterial antibodies primarily for the treatment and prevention of hospital-acquired bacterial infection. The partnership combines Crucell’s unique antibody discovery, research and development capabilities with MedImmune’s expertise in clinical development and commercialization of anti-infective antibodies.

 

• www.medimmune.com

Merck

Over the years, Crucell and Merck have developed a close working partnership, entering into a number of agreements. In October 2000, Crucell entered into an agreement with Merck, in which Merck was granted an exclusive license to use Crucell’s PER.C6^® cell line in developing a vaccine against HIV*.

 

In June 2003, Merck and Crucell expanded a Cooperation Agreement whereby the two companies agreed to work closely on matters relevant to maintenance of the PER.C6^® Cell Substrate Biologics Master File. Merck and Crucell further expanded their relationship in December 2006, when both companies signed a cross-licensing agreement for vaccine production technology.

 

* The development of this vaccine was discontinued in September 2007 but this was unrelated to the use of Crucell’s PER.C6^® technology.

 

• www.merck.com 

Novartis

In March 2006, the Korea Food and Drug Administration (KFDA) awarded licensure to Quinvaxem^®, a fully liquid pentavalent pediatric vaccine. The vaccine is produced by Crucell in Korea and was co-developed with Chiron Corporation (now Novartis), which provides four of the five vaccine components as bulk.

 

• www.novartis.com

sanofi pasteur

In December 2003, Crucell signed a strategic agreement with sanofi pasteur to further develop and commercialize novel influenza vaccine products based on Crucell's proprietary PER.C6^® cell line technology. The agreement covers both pandemic and epidemic influenza vaccines.

 

In April 2005, sanofi pasteur, with Crucell as a subcontractor, received a US$97 million contract by the US Department of Health and Human Services (HHS) for clinical development of PER.C6^®-based influenza vaccine and other related activities.

 

In December 2007, Crucell and sanofi pasteur signed an exclusive collaboration and commercialization agreement for Crucell's rabies monoclonal antibodies, next-generation rabies biologicals, to be used with rabies vaccine for post-exposure prophylaxis against this fatal disease.

 

• www.sanofipasteur.com

Wyeth

In July 2007 Crucell entered into a co-exclusive license agreement with Wyeth Pharmaceuticals, a division of Wyeth, for the use of our PER.C6^® and Advac^® technology.

 

In March 2008 both companies entered into an exclusive vaccine development agreement. Crucell is responsible for the development and manufacture of certain components of a vaccine for use by Wyeth in clinical studies. The development activities takes place in Crucell's dedicated vaccine manufacturing facilities in Bern, Switzerland.

 

On January 7th, 2009 Crucell announced that it was in friendly discussions with Wyeth regarding a potential combination of the two companies. On January 26th, 2009 Crucell announced that Wyeth withdrew from these discussions.

 

• www.wyeth.com